We should avoid the indiscriminate use of insulin sensitizers in women with polycystic ovary syndrome.
Azziz
Ricardo
R
Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center and the David Geffen School of Medicine at the University of California, Los Angeles, California, Los Angeles 92248, USA. azzizr@cshs.org
D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D010060:Ovulation / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D014806:Vitamin B 12 Deficiency / Q000139:chemically induced
D007004:Hypoglycemic Agents